Varlitinib: “Of 27 patients evaluable for efﬁcacy assessment, 9 patients showed PR and 13 had SD for more than 6 weeks. ORR and DCR were 33.3% and 81.5% respectively”; Biliary tract cancer

varlitinib (ASLAN001) - ASLAN

Jan 19, 2019